• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Go ahead Mark!...teach us how to sell Edarbi

Quote








So...how we doing? Anyone can monitor us and tell us what we are doing wrong. When are our leaders going to lead and show us how to sell this drug? Isn't that what Mark is there for? Guide us! Manage us! Help us develop! Can you do that? Isn't THAT your job?
 




Isn't this the time when upper management would guide us with all their great knowledge they've gained over years of hard work? Isn't this when we should be given great pearls of wisdom to guide us through troubled waters?


ummm...no. Just self-serving emails to pad their next review and then blame the reps for poor numbers.
 




Ummm...hey guy over here..ahem...

Yeah you guys buddies, you arent supposed to be 'selling' edarbi. Its a filler until we can get our rug pipeline going again. We are acquiring other firms and doing all we can to give our reps real drugs to 'sell'.

Until then just carry the samples in your bags.

Yes you guys.
 












Well, the 1600 people are looking in the wrong place. There is no leadership here at Takeda. Just people with job titles and positions. The water continues to rise as the ship sinks.
 




Top Bottom
Back
Quote